Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...
Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...
Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...
Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...
Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office ...
Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.